ArticleFrontiers in oncology2025
Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenicInternational cancer conference journal · 2026Article
- Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.Journal of neuro-oncology · 2026Article
- Clinical and molecular heterogeneity in advanced-stageFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POLE-mutated endometrial cancers have repeatedly shown to harbor an excellent prognosis. Recurrences or primary advanced disease are rare events in this subgroup. We report three cases of POLE-mutated endometrioid ECs with brain metastases. While patients with CNS metastases from endometrial cancers are very uncommon and generally confer a poor prognosis and limited survival, all cases presented here survived substantially longer than the median survival time of patients with brain metastasis published in the literature. All patients responded well to systemic therapy or radiotherapy. Additionally, we present one case with complete response to only four cycles of pembrolizumab monotherapy. These cases suggest that, even in the setting of brain metastases or recurrent disease, a pathogenic POLE mutation remains a marker for excellent clinical outcome. The question of why these tumors metastasized to the brain in the first place remains to be answered by further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.